{"id":"ffp-cryo","safety":{"commonSideEffects":[{"rate":null,"effect":"Transfusion-related acute lung injury (TRALI)"},{"rate":null,"effect":"Allergic reaction"},{"rate":null,"effect":"Fluid overload"},{"rate":null,"effect":"Transfusion-transmitted infection (rare with modern screening)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fresh Frozen Plasma (FFP) contains multiple coagulation factors and fibrinogen, while Cryoprecipitate is enriched in fibrinogen, von Willebrand factor, and other cold-insoluble proteins. Together, they replenish depleted clotting factors and fibrinogen to correct coagulopathy and control bleeding in critical situations such as massive transfusion, disseminated intravascular coagulation, or severe liver disease.","oneSentence":"FFP/Cryo is a combination blood product therapy that replaces clotting factors and fibrinogen to restore hemostatic function in patients with severe bleeding or coagulopathy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:43.998Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe bleeding with coagulopathy"},{"name":"Massive transfusion protocol"},{"name":"Disseminated intravascular coagulation (DIC)"},{"name":"Fibrinogen deficiency or dysfunction"}]},"trialDetails":[{"nctId":"NCT07437755","phase":"NA","title":"Thrombelastometry-guided Blood Component Administration Versus Standard of Care in Patients With Decompensated Liver Cirrhosis Undergoing Invasive Procedures","status":"RECRUITING","sponsor":"Grigore T. Popa University of Medicine and Pharmacy","startDate":"2025-06-01","conditions":"Liver Cirrhosis With Acute Decompensation","enrollment":116},{"nctId":"NCT03444324","phase":"PHASE3","title":"Adjusted Fibrinogen Replacement Strategy","status":"COMPLETED","sponsor":"Biotest","startDate":"2018-04-03","conditions":"Bleeding Disorder, Hypofibrinogenemia; Acquired","enrollment":222},{"nctId":"NCT06153082","phase":"NA","title":"Rotational Thromboelastometry [ROTEM] vs Thromboelastography [TEG] Guided Blood Component Use in Patients With Cirrhosis of Liver With Non-variceal Bleeding.","status":"RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2023-12-16","conditions":"Liver Cirrhosis","enrollment":80},{"nctId":"NCT05734001","phase":"NA","title":"Rotational Thromboelastometry Versus Conventional Haemostatic Tests in Children With Decompensated Cirrhosis Undergoing Invasive Procedures.","status":"RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2022-11-18","conditions":"Decompensated Cirrhosis","enrollment":90},{"nctId":"NCT03045068","phase":"PHASE4","title":"Platelet Transfusion During Neonatal Open Heart Surgery","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2017-04-11","conditions":"Cardiac Disease, Cardiac Surgery, Cardiopulmonary Bypass","enrollment":46},{"nctId":"NCT04460222","phase":"NA","title":"Rotational Thromboelastometry Guided Blood Component Use in Children With Cirrhosis Undergoing Invasive Procedures: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2020-11-16","conditions":"Cirrhosis, Liver","enrollment":60},{"nctId":"NCT04514575","phase":"","title":"Plasma Transfusion in Major Vascular Surgery","status":"COMPLETED","sponsor":"Naestved Hospital","startDate":"1997-01-01","conditions":"Aortic Aneurysm, Abdominal, Arterial Occlusive Diseases","enrollment":17000},{"nctId":"NCT00945542","phase":"PHASE1, PHASE2","title":"The Trauma- Formula-Driven Versus Lab-Guided Study (TRFL Study)","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2009-07","conditions":"Hemorrhagic Shock, Trauma Coagulopathy","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fresh Frozen Plasma","Cryoprecipitate"],"phase":"phase_3","status":"active","brandName":"FFP/Cryo","genericName":"FFP/Cryo","companyName":"Biotest","companyId":"biotest","modality":"Biologic","firstApprovalDate":"","aiSummary":"FFP/Cryo is a combination blood product therapy that replaces clotting factors and fibrinogen to restore hemostatic function in patients with severe bleeding or coagulopathy. Used for Severe bleeding with coagulopathy, Massive transfusion protocol, Disseminated intravascular coagulation (DIC).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}